**The urgent need for a harmonized severity scoring system for acute allergic reactions**

**Authors:** Antonella Muraro1\*, Montserrat Fernandez-Rivas2\*, Kirsten Beyer3, Victòria Cardona4, Andrew Clark5, Esben Eller6, Jonathan O’B Hourihane7, Marek Jutel8, Aziz Sheikh9, Ioana Agache10, Katrina J Allen11, Liz Angier12, Barbara Ballmer-Weber13, Maria Beatrice Bilò14, Carsten Bindslev-Jensen6, Carlos A. Camargo, Jr 15, Antonella Cianferoni16, Audrey DunnGalvin7, Philippe A Eigenmann17, Susanne Halken18, Karin Hoffmann-Sommergruber19, Susanne Lau20, Caroline Nilsson21, Lars K. Poulsen22, Franziska Rueff23, Jonathan Spergel24, Gunter Sturm25, Frans Timmermans26, Maria J Torres27, Paul Turner28, Ronald van Ree29, Magnus Wickman30*,* Margitta Worm31, E. N. Clare Mills32\*, Graham Roberts33-35\*

\*Equal contribution

**Affiliations:**

1. Food Allergy Referral Centre Veneto Region Department of Women and Child Health Padua General University Hospital, Italy

2. Allergy Department, Hospital Clinico San Carlos, Madrid, Spain

3. Department of Pediatric Pneumology & Immunology, Charité Universitätsmedizin Berlin, Germany

4. Allergy Section, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain

5. Allergy Section, Department of Medicine, University of Cambridge, Cambridge, UK

6. Odense Research Center for Anaphylaxis, Dept. Dermatology & Allergy Center, Odense University Hospital, Odense, Denmark

7. Paediatrics and Child Health, University College Cork, Ireland

8. Wroclaw Medical University, Poland

9. Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh.

10. Transylvania University Brasov, Faculty of Medicine, Department of Allergy and Clinical Immunology, Brasov, Romania

11. Murdoch Children’s Research institute, Department of Allergy Royal Children’s Hospital, University of Melbourne Department of Paediatrics, Australia and the University of Manchester, UK

12. Department of Immunology and Allergy, Northern General Hospital, Sheffield, UK

13. Allergy Unit, Department of Dermatology, University Hospital Zürich, Zürich, Switzerland

14. Allergy Unit, Department of Internal Medicine, University Hospital of

Ancona, Italy

15. Department of Emergency Medicine, Massachusetts General Hospital, Boston, USA

16. Allergy And immunology Division, Department of Pediatrics, Perelman School of Medicine, The University of Pennsylvania, The Children’s Hospital of Philadelphia

17. Pediatric Allergy Unit, Department of Pediatrics, University Hospitals of Geneva, Geneva Switzerland

18. Hans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark

19. Dept. of Pathophysiology and Allergy Research, Medical University of Vienna, Austria

20. Department of Pediatric Pneumology and Immunology, Charité Universitätsmedizin Berlin, Germany

21. Department of Clinical Science and Education, Karolinska Institutet and Sachs´ Children´s Hospital, Stockholm, Sweden

22. Allergy Clinic, Copenhagen University Hospital, Copenhagen, Denmark

23. Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, Munich, Germany

24. The Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, USA

25. Department of Dermatology and Venerology, Medical University of Graz & Outpatient Allergy Clinic Reumannplatz, Vienna, Austria

26. Netherlands Anafylaxis Network, The Netherlands

27. Allergy Unit, IBIMA, Regional University Hospital of Malaga, UMA, Málaga, Spain

28. Section of Paediatrics (Allergy and Infectious Diseases) & MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, UK

29. Departments of Experimental Immunology and of Otorhinolaryngology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

30. Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden, Sachs’ Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden

31. Department of Dermatology and Allergy, Charité-Universitätsmedizin, Berlin, Germany

32. Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK.

33. NIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK

34. Clinical and Experimental Sciences and Human Development in Health Academic Unit, University of Southampton Faculty of Medicine, Southampton, UK

35. The David Hide Asthma and Allergy Research Centre, St Mary’s Hospital, Isle of Wight, UK.

**Address for correspondence:**

Antonella Muraro, MD, PhD, Head of the Referral Centre for Food Allergy Diagnosis and Treatment, Veneto Region, Department of Mother and Child Health, University of Padua, Via Giustiniani 3, 35128 Padua, Italy.

Tel.: +39-049-821-2538

Fax: +39-049-821-8091

E-mail: muraro@centroallergiealimentari.eu

**Word count:** 3800

**Key words:** allergic reactions, anaphylaxis, angioedema, asthma, development, drug allergy, food allergy, severity score, urticarial, validation, venom allergy,

**Abstract**

The accurate assessment and communication of the severity of acute allergic reactions is important to patients, clinicians, researchers, the food industry, public health and regulatory authorities. Severity has different meanings to different stakeholders with patients and clinicians rating the significance of particular symptoms very differently. Many severity scoring systems have been generated, most focusing on the severity of reactions following exposure to a limited group of allergens. They are heterogeneous in format, none has used an accepted developmental approach and none has been validated. Their wide range of outcome formats has led to difficulties with interpretation and application. Therefore there is a persisting need for an appropriately developed and validated severity scoring system for allergic reactions that works across the range of allergenic triggers and addresses the needs of different stakeholder groups. We propose a novel approach to develop and then validate a harmonized scoring system for acute allergic reactions, based on a data-driven method that is informed by clinical and patient experience and other stakeholders’ perspectives. We envisage two formats: (i) a numerical score giving a continuum from mild to severe reactions that is clinically meaningful and is useful for allergy healthcare professionals and researchers; and (ii) a three grade based ordinal format that is simple enough to be used and understood by other professionals and patients. Testing of reliability and validity of the new approach in a range of settings and populations will allow eventual implementation of a standardized scoring system in clinical studies and routine practice.

**Introduction**


IgE-mediated allergy affects people of all age groups across the world (1). Allergic reactions are triggered by a wide range of allergen sources including foods, stinging insects, house dust mite, pollens, moulds, drugs and animal dander, causing manifestations affecting many different organ systems. Although most are IgE mediated allergic reactions, there are overlapping presentations with other pathophysiologies (eg anaphylactoid reactions). Severity of reactions vary, both between episodes within the same individual and between different individuals (2). Symptoms range from mild, self-limiting local reactions to life-threatening anaphylaxis. Perception is critical, with different stakeholders often having very different views about the apparent severity of the same reaction. These differences are important because the severity of a reaction guides both the immediate and long-term management of the patient (3). It is therefore vital to be able to describe accurately the severity of previous reactions to optimize both immediate care decisions and ongoing patient management. Moreover, there is a need to grade severity, to standardize patient monitoring, to define severity in participants in clinical studies, such as immunomodulation therapy, as well as facilitate risk assessment and management by, for example, the food industry and public health authorities.

Many scoring systems have been developed to describe the severity of allergic reactions for venom (4,5), food (6-11), drugs (12,13) and adverse reactions to allergen immunotherapy (14,15). Some specifically mention anaphylactoid reactions (12,13); at least some of these are likely to represent anaphylaxis (absence of specific IgE is not reported) and as so are included. Although these have all been developed to assist patients and healthcare professionals correctly manage reactions, there is considerable heterogeneity in the approaches employed in these systems. Consequently, we lack a single, standardized approach to quantifying the severity of allergic reactions to all triggers that can be used by all stakeholder. The European Union-funded iFAAM project, in collaboration with a task force of the EAACI Food Allergy and Anaphylaxis Initiative, critically reviewed the currently available systems, considered the challenges to generating scoring systems and proposed an approach to developing a harmonized system to quantify the severity of allergic reactions. In addition, recommendations were made as to how such a new scoring system could be validated. Our ultimate aim is in due course to develop a new severity scoring system for allergic reactions that can be utilized in different scenarios, in order to improve patient care and facilitate the needs of other stakeholders.

**Why do we need a severity scoring system for acute allergic reactions?**

A severity scoring system for allergic reactions may assist clinicians in at least two ways: providing a summary of a reaction reported by a patient or carers and providing a summary of an allergic reactions within the context of a challenge or immunotherapy undertaken in a clinical environment. The score should contribute to determining appropriate emergency treatment plans. Other important stakeholders are likely to have somewhat different views as to why a harmonized severity scoring system is required for allergic reactions (Table 1). For example, a patient might better utilize a simpler system that can be readily recalled in an emergency and directly links to emergency therapy (Figure 1). Although the level of detail required by each stakeholder may vary, there is an intrinsic benefit in having a harmonized system that all stakeholders can utilize. This would facilitate communication in terms of the nature of specific reactions and how they should be managed. At its simplest level, a harmonized scoring system could divide allergic reactions into a small number of grades with very different severities on the basis of easily recognized symptoms and signs. Each major grade might have a number of subgrades to provide additional detail that might be useful to an allergy healthcare professional or researcher. A validated disease severity scoring system could be used both to standardize patient monitoring and to define patient cohorts in clinical studies.

**Figure 1. Illustration of how a severity scoring system could be used to guide the management of acute allergic reactions**

****

As severity increases with increasingly severe symptoms, adrenaline is more likely to be indicated. The exact symptoms when adrenaline is indicated needs to be individualised for different patients and for different situations by their healthcare professional as each will have a different risk profile. The figure is only an illustration with different severity sequences seen for different allergens and different patients. Additionally therapies such as oxygen and corticosteroids may also be indicated. Figure reproduced with permission from Muraro et al (3).

**The meaning or perception of severity in relation to acute allergic reactions**

The term severity has different meanings to different subgroups of patients, to health care professionals, researchers, the food industry, public health authorities or other stakeholders. All these perspectives need to be explored to understand the differing needs and concerns of each of these groups. A dictionary definition describes severity “as the degree of affliction suffered due to a condition or stressor” or “the degree of pain or harm from a medical condition”. Asevere reaction should be considered either as one causing disruption to the activities of daily life or an event that leads to an otherwise unanticipated healthcare utilization.

It is important to recognize that “severity” is a continuum, which may be dynamic: a person having a mild reaction (e.g. mild angioedema) may progress to severe symptoms (e.g. bronchospasm) within a few minutes. There may be temporal differences in severity from one allergen exposure event to another, possibly due to a genuine change in a patient’s clinical status, a change of dose of allergen or the addition of augmentation or co-factors that can exacerbate allergic reactions (16-18). Perceived severity depends on subjective interpretation of symptoms and can also vary depending on what else may be going on in an individual’s life (e.g. stress at work or home, other chronic disorders, level of risk aversion and co-factors), and on whether they are a patient or a carer.

We believe it is helpful to consider severity of allergic reactions from the perspective of each of the key stakeholders.

*Allergic individuals and their carers:* patients and their carers tend to under- or over-estimate the potential severity of severe allergic reactions and they may not seek medical help (19).For example, clinical experience shows that families often consider angioedema in the context of an allergic reaction to be much more significant than mild wheeze; their allergy-experienced physicians are likely to disagree considering wheeze to be more severe (and potentially life-threatening). Patients and their carers may be used to wheezing with viral infections and therefore treat allergen-induced wheezing with their usual asthma treatments not appreciating that, in this context, the bronchospasm and resulting symptoms may worsen rapidly. Any disruption to daily life can be reasonably considered by the family to be a significant or severe event: for example, missing a day of school due to urticaria or visiting the emergency department due to anaphylaxis.

*Family doctors* rarely encounter allergic reactions and may not have had training, the clinical experience or sufficient time within the consultation to assess their severity. Adrenaline (epinephrine) may be prescribed when it is not indicated or a patient may be referred to the emergency department when an allergic reaction is not potentially life-threatening. Conversely, the severity may be under-appreciated and the reaction only treated with antihistamines and corticosteroids instead of adrenaline (20).

*Emergency department physicians* and first responders in the community may not appreciate the allergic origin of clinical scenarios that they encounter. The differential diagnosis for anaphylaxis is very broad (21). So, in the absence of any objective point of care diagnostic test, the constellation of symptoms and signs caused by severe multi-system allergic reactions (anaphylaxis) must be recognized if correct emergency treatment is to be initiated.

*Allergy specialists*are trained to recognize the clinical spectrum of allergic diseases and to pragmatically evaluate their patients’ previous reactions. An accurate evaluation of severity is required to determine emergency treatment and personalise care plans. Most allergists do not see their patients during acute allergic reactions so there is a need to accurately, but retrospectively, assess the potential severity.

*Health psychologists* need to be able to separate the physiological symptoms of allergic disease from the psychological impact and determine the impact that is due to any psychological co-morbidities. Such an analysis has profound implications for correct treatment and management and for alleviating patient/parent anxiety and concerns.

*Food industry and public health bodies* may consider a severe outcome to be any change in a person’s quality-of-life, unscheduled access to medical care, loss of time at work, school or studies.

While there are clear differences between the perspectives and needs of these different stakeholders, there is also considerable overlap and this could feed into a harmonized approach. A harmonized severity scoring system for allergic reactions ideally needs to take into account the perceptions and needs of different stakeholders. Grades of severity should be distinct to facilitate their utilisation by patients, parents, healthcare professionals and other relevant groups. Ensuring that these grades make sense to other groups who may use the system will be a challenge, but it is essential for any proposed harmonized system that it is accepted by all stakeholders.

**Table 1. Need for a harmonized severity scoring of acute allergic reactions according to different stakeholders**

|  |  |  |
| --- | --- | --- |
| **Stakeholder** | **Purpose** | **Essentials of the system** |
| Patients and their carers | Risk awareness, recognition of symptoms of allergic reaction, recognition of seriousness and decision of type of self-treatment, reassurance. | Requires a simple, easy to remember system to facilitate direct linkage of presentation to management. |
| Emergency department, family doctors and other healthcare professionals | Assessment for acute and long term management according to their competences, decisions about need to refer to specialist, educational purposes | Requires a simple, easy to remember system to facilitate emergency management. |
| Allergy healthcare specialists | Assessment for acute and long-term management, risk assessment and education of patients. | To document the reaction in detail to allow documentation and communication. |
| Food industry | Increase awareness on anaphylaxis, risk assessment of products, risk management | Client-facing sectors (e.g. restaurants) need a simple framework to manage allergic reactions. Risk assessors and managers need numerical scores that can be incorporated in probabilistic models of allergen risk. |
| Public health authorities | Increase awareness on anaphylaxis, to assess outcomes of health policies, funding allocation, health policy prioritization, cost-effectiveness assessment, improve allergic reaction codification, facilitate adrenaline availability, education on anaphylaxis management for lay people (e.g. teachers, children day carers, airline cabin crew) | Require a simple, easy to understand system that can be used by non-healthcare professionals. For regulators a more sophisticated numerical score incorporating probabilistic models of allergen risk would be required. |
| Food, hospitality and catering industries | Increase awareness on anaphylaxis, risk assessment of products, risk management | The food industry (e.g. restaurants) need a simple framework to manage allergic reactions. Risk assessors and managers need numerical scores that can be incorporated in probabilistic models of allergen risk. |
| Researchers | Harmonise terminology in observational and interventional studies, aid comparison of data and interpretation of mechanistic studies | System needs to document the reaction with increased granularity to allow definition, segmentation and analysis |

**What severity scoring systems are currently available?**

Different scoring systems have been proposed to assess the severity of acute allergic reactions. These address allergic reactions induced by food (6-11), drugs (12,13) hymenoptera stings (4,5) and adverse reactions to allergen immunotherapy (14,15). None of these was intended to be widely applied to all types of acute allergic reaction, despite some having been extended in this way (22-26). Data obtained from both clinical trials (6,7,10,14) and emergency room visits or intensive care unit (ICU) admissions (4,5,12,22-25) have formed the backbone of reviews, position papers and consensus reports (9,26-28). However, these scoring systems classify severity in different grades using ordinal scales that are not equivalent across the different scoring systems. Methods range from valuing key symptoms and signs (5-7,13,23) to more complex algorithms e.g. including the exposure dosage (10,22), fulfilment of 2-or-more criteria (4,29), summation of symptoms to assess severity (14,20) or related to number of organs involved and treatment plan (11). Furthermore, some of the classification systems only cover the most severe allergic reactions (i.e. anaphylaxis) (5,15), while others are designed for a wider spectrum of reactions (9,31,32).

Almost all current scoring systems are organ-specific, dividing symptoms and signs according to origin (i.e. the skin, respiratory, gastro-intestinal, cardio-vascular, and nervous system); there is less consistency in terms of which symptoms and signs are included. Skin symptoms usually include pruritus, urticaria, angioedema and flushing/rash. Gastrointestinal features consist mostly of subjective symptoms (e.g. oral allergy syndrome, nausea, and abdominal pain), emesis and diarrhoea. Cardiovascular features include change in heart rate (from tachycardia to cardiac arrest) and different grades of hypotension. Neurological features are less consistent, with grades of anxiety and consciousness (from reduced activity level to total loss of consciousness). The biggest discrepancies are found in respiratory symptoms where some only apply airway obstruction (14), while others incorporate different levels of laryngeal symptoms, wheezing, dyspnea, asthma, cyanosis and respiratory arrest (9). Symptoms from upper airways (i.e. nose and eyes) are covered by some (9,25,28) and excluded by others (4,12,23). No approach has included a full set of symptoms and signs and the heterogeneity of scoring of each symptom/sign is pronounced, with classification ranging from “present” to “mild/moderate/severe” to the 6-grade comprehensive Japanese ASCA-system (30) (not available in English). A more limited number of grades (e.g. mild, moderate and severe or give adrenaline/do not give adrenaline) may be more useful for patients and non-allergy specialists. However, for research purposes, and to inform and validate more simple systems, it may be preferable to have a numerical severity score with more gradations.

Comparison across historical approaches is difficult, but not impossible. Categorical scales would need to be recalculated into comparable numerical values, which would involve difficult decisions about interpretation and categorization of diverse symptoms. This would need to be addressed with caution since comparisons across historical approaches would undoubtedly involve other important differences, such as diverse study populations (community versus hospital), ages (children versus adults), and routes of exposure (food versus hymenoptera venom). Moreover, these comparisons would need to overcome some vague terms without clear definitions and the fact that none of the severity scoring systems is validated nor were any specifically designed for the proposed comparisons.

**What are the challenges associated with developing a single unified severity scoring system for acute allergic reactions?**

The key problem in developing an allergic reaction severity score is the lack of a reliable, evidence-based, gold-standard criterion standard that can be used as a reference for derivation and validation. This is one of the research needs being addressed by the iFAAM study (33) and may provide a better outcome measure to use in generating a severity score. This in itself would need validation across the breadth of clinical allergy. Extending these systems to all allergic reactions is challenging, not least because of possible bias from a non-representative sample, with implications for both reliability and validity. Furthermore, the existing allergy nomenclature is far from being harmonized (34). A better insight into the disease mechanisms underlying different allergic reactions and an endotype-driven approach (35) would help to develop a common methodology across the huge spectrum of allergic disease. The range of allergic triggers, clinical presentations and ages plus the potential geographic diversity creates issues with adequate validation of any scoring system in all the key target populations

**A proposed approach to developing a severity scoring system**

An ideal scoring system for the severity of allergic reactions would be based on easily and routinely recorded variables. It should be applicable to all patient populations and to any acute allergic reaction, regardless of the trigger. A classification of severity of acute allergic reactions also should fulfil two underlying premises: (i) as the severity increases, the number of involved organ systems will usually increase, and (ii) cardiovascular, neurological, bronchial and laryngeal involvement are potentially life-threatening and therefore signify more severe reactions. Ideally, a severity scoring system would have two formats to deal with the two different premises that both have different *raisons d’être* (see above). A continuous numerical system that takes into account the totality of the available clinical data and a simpler form with a small number of discrete grades. Scores from the two formats should each be able to be mapped onto each other. Additionally, scores associated with less severe symptoms or signs should be lower than scores associated with more severe ones.

In the simpler format, severity would be classified into different grades. Such an approach would be mainly intended for the more “routine” clinical management of patients, for non-allergy specialists and perhaps patients. It is therefore suggested that only three grades are included: the mildest reactions (grade 1) would include isolated local reactions of the skin or mucosa at the first contact with the allergen; an intermediate grade (grade 2) would include reactions that involve more distant skin, upper airway and/or gastrointestinal tract; and then the most severe, potentially life-threatening reactions (grade 3) would comprise cardiovascular, neurological, bronchial and/or laryngeal involvement (Figure 2). This 3 level classification system could, for example, be graphically represented with a 3 colour code, yellow-orange-red for grades 1 to 3 (see Figure 2) that would facilitate understanding and wide dissemination in the lay and non-specialist health care communities. It would also facilitate individualised management with patients with different risk profiles advised to use adrenaline at different grades.

In the more nuanced numerical format, the proposed severity scoring system would facilitate the needs of researchers and provide a detailed description of, for example, food challenge outcomes. If the resulting score could be interpreted in relation to the simpler grading system, flexibility would be enhanced making it useful to a wider number of stakeholders. The score would be generated using a list of variables derived by consensus by a multidisciplinary panel of experts. A numerical weighting would be applied to each variable; this weighting could be derived in step 1 by expert consensus (a subjective score) and then in step 2 by utilising a large database of clinical data from patients experiencing acute allergic reactions (an objective score).

A data-driven approach to generate an objective score must be incorporated as it is more likely to produce a valid model. This lends itself to being integrated into, for example, probabilistic models being developed for allergen risk management by the food industry (36). Such an approach would utilize a statistical system to determine which variables to use and the weighting to be applied to each of them. Constructing an objective score would require data from allergic reactions experienced by a large population of patients who have undergone a comprehensive clinical evaluation including all the clinical manifestations of the reactions and a confirmation of their allergy diagnosis by the criterion standard diagnostic test. The challenge is that the severity of each allergic reaction needs to be quantified to provide an endpoint against which a model can be generated using the available clinical variables. Such a criterion standard measure for severity does not currently exist; the best approximate we have is likely to be a consensus severity assessment made by a large multidisciplinary group of experts.

**Figure 2. Proposed simplified classification of severity of acute allergic reactions according to the organ system involved**

|  |  |  |
| --- | --- | --- |
| **Local reactions** | **Systemic reactions** | |
| Grade 1 | Grade 2 | Grade 3 |
| Isolated local allergic reactions of the skin or mucosa at the first contact with the allergen. | Allergic reactions that involve skin away from the site of allergen contact, upper airway and/or gastrointestinal tract. | Severe, potentially life-threatening allergic reactions involving cardiovascular, neurological, bronchial and/or laryngeal symptoms and signs. |

Patients would be assigned to a grade according to their most severe symptom/sign, e.g. grade 2 may include symptoms of grade 1 and grade 2. These grades would be generated using the approach described in the text. Grades would have the ability to be easily translated into clinical management, although individual patient characteristics and circumstances need to be taken into account so that different patients might be instructed to use adrenaline at different grades according to their risk profile.

**How should we validate a new harmonized severity scoring system?**

A new severity scoring system would need to be validated to ensure that it provided an accurate assessment of severity in different populations at different time points. There are a number of accepted steps in this process.

*Face validity* Face validation of an acute allergic reaction severity score is a key step as it assesses whether the intended users are satisfied with and understand the system. Some preliminary work would be required to make a case that the existing multiple systems should be replaced by one harmonised system. It must be made very clear what the new measurement means in terms of benefits for the diverse stakeholders and what type of data and results the tool can - and cannot - provide. For example, an international panel of diverse stakeholders could be asked to review the score to assess whether or not they feel that it is appropriate for their needs. Some refinement will probably be required to ensure that the approach is optimised for use in different clinical setting.

*External validation* The refined new severity scoring system would ideally then need to be validated statistically using external data. Given the aim of developing one harmonized score, this would require extensive research and cover a number of different areas, such as assessing it against the use of adrenaline and high dependency care admission. This likely to prove challenging as both adrenaline use and admission vary between healthcare systems and physicians. Criteria for validity would need to be set in advance.

*Cross-sectional* validity would focus on the ability of the scoring system to differentiate between those experiencing outcomes of varying severities and also in comparing predicted with actual observed outcomes using standard parameters developed to assess the validity of models. An ideal score would need to function in different health settings worldwide, with different triggers, dosages and threshold values and in different age groups and languages.

*Longitudinal validity* is also important. For example, patients who have been treated with an effective immunomodulation therapy might expect to have less severe reactions after treatment although this might be complicated if their threshold/eliciting dose also changes (2). In this respect, the minimal clinically important difference (MCID) (i.e. smallest difference in the score associated with the severity of acute allergic reactions that can be differentiated by an expert allergist) needs to be calculated to assess the resolution of the scoring tool. For clinicians and researchers alike, it is critical that the MCID score is a valid and stable measure. A low MCID value may result in overestimating the positive effects of treatment, whereas a high MCID value may incorrectly classify patients as failing to respond to treatment when in fact the treatment was beneficial.

This validation work would require a large number of clinical databases where the scoring system could be assessed against the best available assessment of severity. Many such data sets already exist. Examples are anaphylaxis registers including the UK registry (37), central European NORA registry (38) and the North American FAAN registry (39): hospital admission data would be available from the UK Imperial PICAnet (40) and the Malaga database (41). All of these databases would need to be carefully assessed in terms of their strengths and limitations, with a combination of datasets providing the best option.

**Impact assessment**

Following derivation and external validation, it is critical to assess whether the new scoring system is used as intended and translates into improved clinical outcomes (e.g. improved decision making in reactions, reduced risk; better quality of life). It is also important to ensure that it does not result in important unintended consequences. This is ideally assessed by using a randomized controlled trial (RCT) in which the new scoring system is compared with usual care; depending on the likely risk of contamination between intervention and control arms, a cluster design may be needed with different trial sites randomized to different arms (45). If a formal experimental design is not possible, a quasi-experimental design could be employed (e.g. an interrupted time series or a controlled before-after design) although it should be noted that these alternative approaches are inherently at increased risk of bias when compared to a RCT.

**Implementation**

Implementation requires local, national and international champions to facilitate the adoption of a new approach so that it becomes embedded in routine care, together with case studies to demonstrate its utility and value to various different stakeholders. This can be promoted with the incorporation of the tool into guidelines or other coding systems, and related efforts to promote diffusion and adoption. (42,43). Education of healthcare professionals and other community professional groups such as teachers is essential, as well as risk assessors and managers in public health authorities and the food, hospitality and catering industries alike. Information technology can also be utilized to promote a new approach by developing for example a decision support engine (44) that stakeholders can use. Finally, demonstrating that a severity scoring system improved clinical outcomes (e.g. better quality of life; reduced risk; improved decision making in reactions) on a population-based level, would promote the further take up of the approach.

**Summary and conclusions**

The accurate assessment and communication of potential severity of acute allergic reactions is important to patients, clinicians, researchers, food industry and public health authorities. Many severity scoring systems are available, usually within the context of one group of allergens sources. However, none of the scoring systems has been developed using the gold standard method for the development of measurement and/or prognostic tools. Furthermore, none of these scoring systems has been validated. A validated reaction severity scoring system is needed to standardize patient monitoring. We propose an approach to developing a harmonized scoring system for acute allergic reactions that is based on a data driven method, informed by clinical and patient experience as well as by the perspectives of other stakeholders. We envisage two levels of details: an ordinal three grade based format and a continuous scoring system giving a continuum from mild to severe reactions that is clinically meaningful. This would allow the same system to be used by patients, clinicians, researchers, the food industry and public health regulators. The new approach would need to be tested for reliability and validity using gold standard methods in a range of settings and populations. We propose that common epidemiological, clinical observational and clinical interventional datasets should be collected to promote future collaboration, cross-validation and refinement of the severity scoring system. For a harmonized system to be successful, an implementation strategy would be required and its impact would need to be assessed. Finally, severity should be considered as just one of a range of important aspects of risk assessment and risk management of allergic diseases. To determine the optimal management of a reaction for a patient, assessed severity needs to be integrated with the clinical context, for example the dose of allergen, route of contact, rapidity of onset and other intrinsic (patient-related) and extrinsic factors.

**Contributions of authors**

The EAACI initiative on the severity of allergic reactions was initiated by Antonella Muraro. It has built on work undertaken by Montserrat Fernandez- Rivas in the iFAAM project led by Clare Mills, work by Andrew Clark in the TRACE project and work by Margitta Worm in the NORA project. Additionally it has benefited from Esben Eller’s and Carsten Bindslev-Jensen’s review of all the existing severity scoring systems. Kirsten Beyer, Victòria Cardona, Jonathan O’B Hourihane, Marek Jutel and Aziz Sheikh led the drafting of specific sections of the paper which Graham Roberts used to develop the initial draft manuscript. All the authors reviewed and contributed to the development of the final paper.

**Acknowledgements**

The task group would like to acknowledge the support from the iFAAM, TRACE, Europrevall and NORA e. V. Anaphylaxis Registry study teams in developing the proposed approach to developing and validating a severity scoring system. The group would also like to thank Estelle Simons for her review of the initial draft manuscript which has helped up develop this approach. This activity was initiated and supported by the European Academy of Allergy and Clinical Immunology (EAACI) as part of the Food Allergy and Anaphylaxis Guidelines Initiative.

**References**

1. Nwaru BI, Hickstein L, Panesar SS, Muraro A, Werfel T, Cardona V, Dubois AEJ, Halken S, Hoffmann-Sommergruber K, Poulsen LK, Roberts G, Van Ree R, Vlieg-Boerstra BJ, Sheikh A. on behalf of the EAACI Food Allergy & Anaphylaxis Guidelines Group. The epidemiology of food allergy in Europe: a systematic review and meta-analysis. Allergy 2014; 69: 62-75.

2. Paul J. Turner, Joseph L. Baumert, Kirsten Beyer, Robert Boyle, Chun-Han Chan, Andrew Clark, René W.R. Crevel, Audrey DunnGalvin, Montserrat Fernández Rivas, M. Hazel Gowland, Linus Grabenhenrich, Sarah Hardy, Geert F Houben, Jonathan O’B Hourihane, Antonella Muraro, Lars K. Poulsen, Katarzyna Pyrz, Benjamin C. Remington, Sabine Schnadt, Ronald van Ree, Carina Venter, Margitta Worm, E.N. Clare Mills, Graham Roberts, Barbara K. Ballmer-Weber. Can we identify patients at risk of life-threatening allergic reactions to food? Allergy 2016; 71: 1241-1255.

3. Muraro A, Roberts G, Worm M, Bilò MB, Brockow K, Fernández Rivas M, et al; EAACI Food Allergy and Anaphylaxis Guidelines Group. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology.Allergy. 2014 ;69:1026-45

4. Mueller HL. Further experiences with severe allergic reactions to insect stings. N Engl J Med. 1959 Aug 20;261:374-7. PubMed PMID: 14424947.

5. Reisman RE. Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. J Allergy Clin Immunol. 1992 Sep;90(3 Pt 1):335-9. PubMed PMID: 1345753.

6. Hourihane JO, Kilburn SA, Dean P, Warner JO. Clinical characteristics of peanut allergy. Clin Exp Allergy. 1997 Jun;27(6):634-9. PubMed PMID: 9208183.

7. Ewan PW, Clark AT. Long-term prospective observational study of patients with peanut and nut allergy after participation in a management plan. Lancet. 2001 Jan 13;357(9250):111-5. PubMed PMID: 11197398.

8. Cianferoni A, Garrett JP, Naimi DR, Khullar K, Spergel JM. Predictive values for food challenge-induced severe reactions: development of a simple food challenge score. Isr Med Assoc J. 2012 Jan;14(1):24-8. PubMed PMID: 22624438.

9. Sampson HA. Anaphylaxis and emergency treatment. Pediatrics. 2003 Jun;111(6 Pt 3):1601-8. Review. PubMed PMID: 12777599.

10. Hourihane JO, Grimshaw KE, Lewis SA, Briggs RA, Trewin JB, King RM, Kilburn SA, Warner JO. Does severity of low-dose, double-blind, placebo-controlled food challenges reflect severity of allergic reactions to peanut in the community? Clin Exp Allergy. 2005 Sep;35(9):1227-33. PubMed PMID: 16164452.

11. Astier C, Morisset M, Roitel O, Codreanu F, Jacquenet S, Franck P, Ogier V, Petit N, Proust B, Moneret-Vautrin DA, Burks AW, Bihain B, Sampson HA, Kanny G. Predictive value of skin prick tests using recombinant allergens for diagnosis of peanut allergy. J Allergy Clin Immunol. 2006 Jul;118(1):250-6. PubMed PMID: 16815163.

12. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977 Feb 26;1(8009):466-9. PubMed PMID: 65572.

13. Ring J. Anaphylactoid reactions to intravenous solutions used for volume substitution. Clin Rev Allergy. 1991 Fall-Winter;9(3-4):397-414. Review. PubMed PMID: 1723655.

14. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC. The Hymenoptera venom study. III: Safety of venom immunotherapy. J Allergy Clin Immunol. 1990 Nov;86(5):775-80. PubMed PMID: 2229842.

15. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol. 1998 Mar;101(3):298-305. PubMed PMID: 9525443.

16. Niggemann B, Beyer K. Factors augmenting allergic reactions. Allergy 2014; 69: 1582–1587. DOI: 10.1111/all.12532

17. Hompes S, Dölle S, Grünhagen J, Grabenhenrich L, Worm M. Elicitors and co-factors in food-induced anaphylaxis in adults. Clinical and Translational Allergy 2013, 3:38.

18. Smith PK, Hourihane JO’B, Lieberman P Risk multipliers for severe food anaphylaxis World Allergy Organ J. 2015 Nov 24;8(1):30. www.ncbi.nlm.nih.gov/pubmed/26635908

19. Noimark L, Wales J, Du Toit, G, Pastacaldi, C, Haddad, D, Gardner, J, Hyer W, Vance, G, Townshend, C, Alfaham, M, Arkwright PD, Rao, R, Kapoor S, Summerfield A, Warner JO, Roberts, G. The use of adrenaline autoinjectors by children and teenagers. Clin Exp Allergy 2012; 42: 284–92.

20. Worm M, Moneret-Vautrin A, Scherer K, Lang R, Fernandez-Rivas M, Cardona V, Kowalski ML, Jutel M, Poziomkowska-Gesicka I, Papadopoulos NG, Beyer K, Mustakov T, Christoff G, Bilò MB, Muraro A, Hourihane JO, Grabenhenrich LB. First European data from the network of severe allergic reactions (NORA). Allergy 2014; 69: 1397-404.

21. Simons FE, Ardusso LR, Dimov V, Ebisawa M, El-Gamal YM, Lockey RF, Sanchez-Borges M, Senna GE, Sheikh A, Thong BY, Worm M; World Allergy Organization. World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol. 2013;162: 193-204.

22. Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A, Coulson A, Hartnett L, Nagree Y, Cotterell C, Isbister GK. Anaphylaxis: clinical patterns, mediator release, and severity. J Allergy Clin Immunol. 2013 Nov;132(5):1141-1149.e5. doi: 10.1016/j.jaci.2013.06.015. Epub 2013 Aug 1. PubMed PMID: 23915715.

23. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004 Aug;114(2):371-6. PubMed PMID: 15316518.

24. Cianferoni A, Novembre E, Mugnaini L, Lombardi E, Bernardini R, Pucci N, Vierucci A. Clinical features of acute anaphylaxis in patients admitted to a university hospital: an 11-year retrospective review (1985-1996). Ann Allergy Asthma Immunol. 2001 Jul;87(1):27-32. PubMed PMID: 11476457.

25. Pumphrey RS, Stanworth SJ. The clinical spectrum of anaphylaxis in north-west England. Clin Exp Allergy. 1996 Dec;26(12):1364-70. PubMed PMID: 9027436.

26. Ring J, Behrendt H. Anaphylaxis and anaphylactoid reactions. Classification and pathophysiology. Clin Rev Allergy Immunol. 1999 Winter;17(4):387-99. Review. PubMed PMID: 10829809.

27. Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, Dubois AE, Beyer K, Eigenmann PA, Spergel JM, Werfel T, Chinchilli VM. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol. 2012 Dec;130 (6):1260-74. doi: 10.1016/j.jaci.2012.10.017. PubMed PMID: 23195525.

28. Muraro A, Roberts G, Clark A, Eigenmann PA, Halken S, Lack G, Moneret-Vautrin A, Niggemann B, Rancé F; EAACI Task Force on Anaphylaxis in Children. The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. Allergy. 2007 Aug;62(8):857-71. Epub 2007 Jun 21. PubMed PMID: 17590200.

29. Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res. 1966 Jun;3(4):331-3. PubMed PMID: 4380730.

30. Hino A, Maeda T, Haneda Y, Kobayashi T, Yasui M, Kando N, Ito K. [Establishment of "Anaphylaxis Scoring Aichi (ASCA)," a new symptom scoring system to be used in an oral food challenge (OFC)]. Arerugi. 2013 Aug;62(8):968-79. Japanese. PubMed PMID: 24335424.

31. Sampson HA, van Wijk RG, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, et al. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology–European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol, 130 (2012), pp. 1260–1274

32. Bock SA, Sampson HA, Atkins FM, Zeiger RS, Lehrer S, Sachs M, Bush RK, Metcalfe DD. Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure: a manual. J Allergy Clin Immunol. 1988 Dec;82(6):986-97. Review. PubMed PMID: 3060514.

33. iFAAM http://www.inflammation-repair.manchester.ac.uk/iFAAM/, accessed 12th September 2017

34. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832-6.

35. Hogan SP, Wang YH, Strait R, Finkelman FD. Food-induced anaphylaxis: mast cells as modulators of anaphylactic severity.Semin Immunopathol. 2012;34:643-53.

36. DunnGalvin A, Chan C-H, Crevel R, Grimshaw K, Poms R, Schnadt S, Taylor SL, Turner P, Allen KJ, Austin M, Baka A, Baumert JL, Baumgartner S, Beyer K, Bucchini L, Fernández-Rivas M, Grinter K, Houben GF, Hourihane J, Kenna F, Kruizinga AG, Lack G, Madsen CB, Mills ENC, Papadopoulos NG, Alldrick A, Regent L, Sherlock R, Wal J-M, Roberts G. Precautionary allergen labelling: perspectives from key stakeholder groups. Allergy 2015; 70: 1039-51.

37. UKfar – UK - Manchester Anaphylaxis Registry - http://www.cmft.nhs.uk/royal-infirmary/our-services/allergy, accessed 12 September 2017.

38. Grabenhenrich LB, Dölle S, Moneret-Vautrin A, Köhli A, Lange L, Spindler T, Ruëff F, Nemat K, Maris I, Roumpedaki E, Scherer K, Ott H, Reese T, Mustakov T, Lang R, Fernandez-Rivas M, Kowalski ML, Bilò MB, Hourihane JO, Papadopoulos NG, Beyer K, Muraro A, Worm M. Anaphylaxis in children and adolescents: The European Anaphylaxis Registry. J Allergy Clin Immunol, in press,

39. Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006 1. J Allergy Clin Immunol. 2007;119(4):1016-8.

40. PICAnet - http://www.picanet.org.uk/, accessed 12th September 2017

41. Gomez F, Aranda A, Campo P, Diaz-Perales A, Blanca-Lopez N, et al. (2014) High Prevalence of Lipid Transfer Protein Sensitization in Apple Allergic Patients with Systemic Symptoms. PLoS ONE 9(9): e107304. doi:10.1371/journal.pone.0107304.

42. Luciana Tanno, Moises Calderon, Nikolaos Papadopoulos, Pascal Demoly, on behalf of the EAACI/WAO Task force of a Global Classification of Hypersensitivity/Allergic diseases. Mapping hypersensitivity/allergic diseases in the International Classification of Diseases (ICD)-11: cross-linking terms and unmet needs. Clinical and Translational Allergy 2015, 5:20 (3 June 2015)

43. Luciana Tanno, Moises A Calderon, Bruce J Goldberg, Cezmi A Akdis, Nikolaos G Papadopoulos, Pascal Demoly. Categorization of allergic disorders in the new World Health Organization International Classification of Diseases. Clinical and Translational Allergy 2014, 4:42 (28 November 2014)

44. Cresswell K, Majeed A, Bates DW, Sheikh A. Computerised decision support systems for healthcare professionals: an interpretative review. Inform Prim Care. 2012;20(2):115-28.

45. Sheikh A, Smeeth L, Ashcroft R. Randomised controlled trials in primary care: scope and application. Br J Gen Pract. 2002 Sep;52(482):746-51